News

August 8, 2018August 8, 2018

Pilot Study to Evaluate Cosentyx in Bone Health of AS Patients

News

A pilot study will investigate how Cosentyx (secukinumab), which has been approved for some autoimmune disorders, affects bone health in patients with ankylosing spondylitis (AS). The upcoming study — titled “The Effects ... Read more

August 6, 2018August 6, 2018

Humira Biosimilar Receives Positive Recommendation from European Medicines Agency Committee

News

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Hulio, a biosimilar to Humira, for the treatment of a number of chronic inflammatory ... Read more

August 1, 2018August 1, 2018

Blocking IL-23 Not Sufficient to Treat Ankylosing Spondylitis, Phase 2 Trial Finds

News

Inhibiting IL-23, a molecule involved in inflammation, was not found to be clinically meaningful to treat ankylosing spondylitis, according to the results from a Phase 2 trial. The study, ... Read more

July 30, 2018July 30, 2018

Fatigue Linked to Work Disability in Ankylosing Spondylitis Patients, Study Shows

News

Higher levels of fatigue are related to the degree of disability at work among ankylosing spondylitis (AS) patients treated with the biologic therapy Enbrel (etanercept), an observational study shows. The ... Read more

July 9, 2018July 9, 2018

Sandoz’s Biosimilar Zessly Approved in EU to Treat AS, Other Conditions

News

The European Commission has approved Sandoz’s biosimilar Zessly (infliximab) to treat all indications of its reference medicine Remicade (infliximab), including ankylosing spondylitis (AS). “The European Commission approval for Zessly ... Read more

July 2, 2018July 2, 2018

Eli Lilly Announces Positive Results from Its 2nd Phase 3 Trial of Ixekizumab

News

Treatment with Eli Lilly’s monoclonal antibody Taltz (ixekizumab) significantly improved the signs and symptoms of ankylosing spondylitis in patients participating in a Phase 3 clinical trial, results show. The study, called COAST-W (NCT02696798), met ... Read more

June 27, 2018June 27, 2018

#EULAR2018 – Combo of TNF Inhibitors, NSAIDs Fight Long-Term Radiographic Progression of AS

News

Use of nonsteroidal anti-inflammatory drugs (NSAIDs) in addition to tumor necrosis factor (TNF) inhibitors provides stronger long-term protective effects in patients with ankylosing spondylitis, according to recent clinical trial ... Read more

June 25, 2018June 25, 2018

Cosentyx Added to Public Drug Programs Across Canada for Adults with Ankylosing Spondylitis

News

Ontario, along with other regions in Canada, will now reimburse Cosentyx (secukinumab) under its public drug program for certain adult patients with ankylosing spondylitis (AS) and active psoriatic arthritis ... Read more

June 20, 2018June 20, 2018

#EULAR2018 – Latest Clinical Data on Cosentyx Reinforces Its Potential to Treat Ankylosing Spondylitis

News

Latest clinical data on Cosentyx (secukinumab) demonstrates its long-term potential to prevent radiographic progression and improve the quality of life of patients with ankylosing spondylitis. Several relevant studies were ... Read more

June 18, 2018June 18, 2018

#EULAR2018 – Phase 2 Trial Results Show Bimekizumab Leads to Improvements in AS Activity

News

The investigative therapy bimekizumab showed significant potential in reducing disease activity and it provided clinically meaningful improvements in ankylosing spondylitis (AS) patients, according to Phase 2b clinical trial data. UCB Pharma recently presented ... Read more

Pin It on Pinterest